ProtAffin Biotechnologie AG

ProtAffin has begun clinical testing of its lead product candidate, the anti-inflammatory PA401AG, a modified form of the human chemokine IL-8. The move is a "major milestone" for the company, said CE

Scrip Intelligence has released its latest Roundtable discussion, Capital Efficiency: Managing Biotechs in Straitened Times . In London at the beginning of December, Scrip Intelligence hosted a Ro

Scrip Intelligence has released its latest Roundtable discussion, Capital Efficiency: Managing Biotechs in Straitened Times . In London at the beginning of December, Scrip Intelligence hosted a Ro

ProtAffin has received further funding from the Austrian public funding body FFG for its preclinical chronic obstructive pulmonary disease (COPD) candidate PA401. FFG has given ProtAffin €2.7 million